RxDoctor Payments Data

Charles Lowe, MD

Allergy & Immunology · Pikeville, KYNPI 1104854207

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,080 of the $11,290 with a category attached, or 89.3%. Teva Pharmaceuticals USA, Inc. accounts for 90.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $10,467 and has fallen 98.7% since, to $140 in 2025.

$11,290in general payments, 2019–2025

Across 76 payments — averaging $148.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$10K
  • AstraZeneca$494
  • GSK$184
  • Regeneron Healthcare Solutions, Inc.$130
  • Novartis$81
  • Merck$66
  • plus $132 from 5 others

What the payments were for

  • Speaking & faculty fees$10,08089%
  • Food & beverage$1,18711%
  • Education$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,290 in reported general payments places this provider in the 65th percentile of 66 allergy & immunology providers in Kentucky.

See all allergy & immunology providers in Kentucky

Medicare billing

Part B allowed, 2024
$41,870
Medicare patients
115
Services billed
3,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab11$29,490
Advair HfaFluticasone Propion/Salmeterol53$25,369
Qvar RedihalerBeclomethasone Dipropionate74$22,574
DuleraMometasone/Formoterol26$13,856
Desloratadine524$12,572
Epinephrine45$11,902
Mometasone Furoate158$9,873
Fluticasone Propionate HfaFluticasone Propionate28$8,300
Breo ElliptaFluticasone/Vilanterol13$8,125
QnaslBeclomethasone Dipropionate19$5,978
Levocetirizine Dihydrochloride685$5,133
Flunisolide73$3,038
Montelukast Sodium499$2,889
Ipratropium Bromide57$1,593
Hydroxyzine Hcl87$1,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl$10,203$28,55293 claims
MerckDulera$66$13,85626 claims
GSKBreo Ellipta$184$8,12513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 66 allergy & immunology providers in Kentucky.

Other allergy & immunology in Pikeville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →